BG
ACRS icon

Bollard Group’s Aclaris Therapeutics ACRS Stock Holding History

Bollard Group’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.62M Sell
431,631
-372,814
-46% -$1.26M 0.05% 96
2025
Q4 		$2.42M Sell
804,445
-421,031
-34% -$1.06M 0.06% 79
2025
Q3 		$2.33M Sell
1,225,476
-126,800
-9% -$221K 0.05% 83
2025
Q2 		$1.92M Sell
1,352,276
-71,900
-5% -$97.3K 0.04% 89
2025
Q1 		$2.18M Buy
+1,424,176
New +$3.04M 0.06% 83

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Bollard Group's ACRS Position: Q1 2026 in Review

Bollard Group reduced its Aclaris Therapeutics (ACRS) stake by 46% in Q1 2026, selling an estimated $1.26M and leaving 431,631 shares worth $1.62M. The position accounts for 0.05% of the portfolio, ranked #96.

Bollard Group first reported a position in ACRS in Q1 2025 and has held it in 5 quarters since. The position peaked at $2.42M in Q4 2025. 136 funds tracked by Wall St. Rank hold ACRS as of Q1 2026.

  • Bollard Group held 431,631 shares of Aclaris Therapeutics worth $1.62M as of Q1 2026.
  • Bollard Group sold 372,814 Aclaris Therapeutics shares in Q1 2026, an estimated $1.26M.
  • Aclaris Therapeutics made up 0.05% of Bollard Group's portfolio in Q1 2026, its #96 holding.
  • Bollard Group first reported a position in Aclaris Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • Bollard Group's Aclaris Therapeutics position peaked at $2.42M in Q4 2025.
  • 136 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2026.

Based on Bollard Group's 13F filing for Q1 2026, filed 14 May 2026.